Moderna Chief Executive Officer Stéphane Bancel sees significant growth opportunities for his company and messenger RNA-based vaccines.
Thermo Fisher Scientific launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as the company engages in more large-scale cohort studies and clinical research.
Although there have been discussions about using different Covid-19 vaccines in combination, World Health Organization (WHO) chief scientist Soumya Swaminathan warned against it, calling it a “dangerous trend.”
Data from a mid-stage clinical study of an experimental vaccine candidate developed by Affinivax and Astellas Pharma for Streptococcus pneumoniae shows ASP3772 is well tolerated and generated an antibody response against the deadly bacterial infection.
A study found potential in a novel gene therapy method to help children born with a rare genetic and neurodegenerative disorder, AADC deficiency.
Australian scientists say they have developed the “holy grail” of blood sugar testing for diabetics, a non-invasive strip that checks glucose levels via saliva.
Los Angeles-based biopharmaceutical firm Enochian BioSciences received a green light from the U.S. Food and Drug Administration for feedback on a possible cure for infections caused by the hepatitis B virus (HBV).
Israel is partnering with U.S.-based NRx Pharmaceuticals to complete trials and commercialize the Israeli-developed Covid-19 vaccine BriLife.
Galapagos announced new post-hoc analyses for the Belgium-based company’s Phase III SELECTION program for the JAK1 inhibitor filgotinib for ulcerative colitis, touting rapid symptom improvement and sustained steroid-free remission.
Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp.’s experimental heart therapy PRX004 in a deal that could be worth up to $1.23 billion, the companies said on July 12.
